Aug 2026· International Journal of Research Publication and Reviews· 0 citations
TL;DR
Accumulating experimental and clinical evidence indicates that bacteriophage therapy could become an important component of future antimicrobial strategies, and Continued multidisciplinary research, standardized clinical protocols, and well-designed randomized clinical trials are essential to establish its long-term efficacy and safety.
Abstract
The rapid emergence and global dissemination of antimicrobial-resistant (AMR) bacteria have significantly reduced the effectiveness of conventional antibiotics, posing a major threat to modern healthcare. The increasing prevalence of multidrug-resistant pathogens, coupled with the slow development of new antimicrobial agents, has renewed interest in alternative therapeutic strategies. Among these, bacteriophage (phage) therapy has re-emerged as a promising biological approach due to its ability to selectively infect and eliminate bacterial pathogens while preserving the normal microbiota. Unlike broad- spectrum antibiotics, bacteriophages exhibit high host specificity, self-replicate at the site of infection, and can effectively disrupt bacterial biofilms, making them particularly attractive for treating chronic and drug-resistant infections. This review critically examines the biological characteristics of bacteriophages, their mechanisms of antibacterial action, therapeutic applications, advantages, and current limitations. Recent advances in phage engineering, genome editing, phage cocktails, encapsulation technologies, and combination therapies with antibiotics are also discussed, highlighting their potential to improve treatment efficacy and overcome bacterial resistance. Furthermore, the review evaluates findings from recent preclinical and clinical studies, regulatory challenges, manufacturing considerations, and safety issues that currently limit the widespread clinical implementation of phage therapy. Although several scientific and regulatory hurdles remain, accumulating experimental and clinical evidence indicates that bacteriophage therapy could become an important component of future antimicrobial strategies. Continued multidisciplinary research, standardized clinical protocols, and well-designed randomized clinical trials are essential to establish its long-term efficacy and safety. With ongoing advances in molecular biology, synthetic biology, and precision medicine, bacteriophage therapy has the potential to complement or, in selected clinical situations, replace conventional antibiotics in the management of multidrug-resistant bacterial infections.
CRISPR-based engineering and genome refactoring highlight the potential of phage-based therapeutics as complements to conventional antimicrobial therapy, although their broader use depends on overcoming biological, clinical, and regulatory challenges.
Bi-Yi Zhang, Xu-Tong Shu, A. Masud et al.· Frontiers in Cellular and In...· 2 citations
The increasing clinical evidence shows that synthetic biology can effectively overcome the inherent defects of natural bacteriophages, confirming the safety and initial efficacy of bacteriophage therapy.
Xuan Wang, Haolin Zhou, T. S. Lim et al.· International Journal of Mol...· 0 citations
This review systematically analyzes major challenges restricting clinical application, such as standardized production, quality control, pharmacokinetic characterization, rapid pathogen identification, and regulatory adaptation, as well as the limited performance of fixed phage cocktails against genetically heterogeneo...
This review comprehensively examines the current landscape of phage therapy, beginning with the modern, genome-based classification of phages and detailing their key therapeutic advantages, including high specificity, self-amplification, and biofilm-penetrating capability.
Lejia Zhao, Yirui Wan, S. Leung et al.· Molecular Biology Reports· 2 citations
Abstract Antimicrobial resistance is considered one of the greatest threats to global public health, being responsible for millions of deaths annually. Bacteria such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa have developed resistance to multiple classes of antibiotics...
D. Kirst, E. Sisti, A. P. Becker· Brazilian Journal of Biology· 0 citations
Key aspects of phage biology that underpin the effective use of phages for therapy are explored, and clinical strategies for applying phages against a range of infections are outlined, highlighting their advantages and limitations.
H. Sinclair, R. Lin, N. B. Ben Zakour et al.· Nature Reviews Microbiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.